← Definitive Healthcare Corp.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $118.3m |
$166.2m
+40.43%
|
$222.7m
+34.00%
|
$251.4m
+12.92%
|
$252.2m
+0.31%
|
$241.5m
-4.24%
|
$238.3m
-1.35%
|
|
| Cost of revenue exclusive of amortization | $11.1m |
$19.4m
+75.20%
|
$25.9m
+33.19%
|
$34.7m
+34.31%
|
$40.7m
+17.11%
|
$38.0m
-6.71%
|
$57.1m
+50.43%
|
|
| Gross profit | $87.8m |
$125.5m
+42.82%
|
$180.0m
+43.49%
|
$203.9m
+13.28%
|
$197.5m
-3.17%
|
$183.3m
-7.19%
|
$181.2m
-1.15%
|
|
| Sales and marketing | $34.3m | $56.4m | $89.6m | $94.5m | $83.8m | $81.6m | — | |
| General and administrative | $12.9m | $30.5m | $48.8m | $58.9m | $49.3m | $51.6m | $51.4m | |
| Transaction, integration, and restructuring expenses | $3.8m | $6.3m | $7.9m | $11.5m | $12.2m | $7.6m | — | |
| Total operating expenses | $102.3m | $150.4m | $221.3m | $533.7m | $908.3m | $407.5m | $256.7m | |
| Loss from operations | ($14.4m) |
($25.0m)
-72.94%
|
($41.3m)
-65.18%
|
($329.8m)
-699.26%
|
($710.8m)
-115.53%
|
($224.3m)
+68.45%
|
— | |
| Interest expense | ($36.5m) | ($25.9m) | ($8.4m) | ($15.2m) | ($14.8m) | ($11.3m) | $11.5m | |
| Interest income | — | $29k | $2.8m | $13.6m | $14.6m | $7.0m | $6.2m | |
| Total other income, net | ($36.7m) | ($35.6m) | $1.8m | $21.6m | $77.1m | $15.0m | — | |
| Loss before income taxes | ($51.2m) | ($60.6m) | ($39.4m) | ($308.2m) | ($633.7m) | ($209.3m) | — | |
| Benefit from income taxes | ($62k) | ($675k) | $17.2m | $18.6m | $42.3m | $10.0m | — | |
| Net loss | ($51.2m) | ($61.3m) | ($22.3m) | ($289.6m) | ($591.4m) | ($199.3m) | — | |
| Net loss attributable to Definitive Healthcare Corp. | ($51.2m) | ($17.7m) | ($6.0m) | ($202.4m) | ($413.1m) | ($138.9m) | — | |
| Less: Net loss attributable to noncontrolling interests | $0 | ($10.2m) | ($16.2m) | ($87.2m) | ($178.3m) | ($60.4m) | — | |
| Basic | — | ($0.19) | ($0.06) | ($1.79) | ($3.54) | ($1.30) | ($1.67) | |
| Diluted | — | ($0.19) | ($0.06) | ($1.79) | ($3.54) | ($1.30) | ($170,325,000.00) | |
| Amortization | $19.4m | $21.3m | $16.8m | $12.7m | $14.0m | $20.3m | — | |
| Product development | $11.1m | $18.6m | $34.9m | $42.4m | $36.5m | $34.8m | — | |
| Depreciation and amortization | $40.2m | $38.7m | $40.1m | $39.0m | $37.6m | $35.8m | $35.6m | |
| Goodwill impairment | — | $0 | $0 | $287.4m | $688.9m | $196.1m | $216.8m | |
| Gain on remeasurement of TRA liability | — | — | $9.7m | $23.5m | $76.9m | $21.7m | — | |
| Loss on partial extinguishment of debt | $0 | ($9.9m) | $0 | $0 | $0 | ($507k) | — | |
| Other (expense) income, net | ($222k) | $143k | $10.2m | $23.2m | $411k | ($1.8m) | — |